BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 7845750)

  • 1. A prospective study of vancomycin pharmacokinetics and dosage requirements in pediatric cancer patients.
    Chang D; Liem L; Malogolowkin M
    Pediatr Infect Dis J; 1994 Nov; 13(11):969-74. PubMed ID: 7845750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of malignancy on the pharmacokinetics of vancomycin in infants and children.
    Chang D
    Pediatr Infect Dis J; 1995 Aug; 14(8):667-73. PubMed ID: 8532423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bayesian forecasting of gentamicin pharmacokinetics in pediatric intensive care unit patients.
    Kraus DM; Dusik CM; Rodvold KA; Campbell MM; Kecskes SA
    Pediatr Infect Dis J; 1993 Sep; 12(9):713-8. PubMed ID: 8414796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vancomycin pharmacokinetics and predicted dosage requirements in pediatric cancer patients.
    Abdel Hadi O; Al Omar S; Nazer LH; Mubarak S; Le J
    J Oncol Pharm Pract; 2016 Jun; 22(3):448-53. PubMed ID: 26079639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vancomycin pharmacokinetics in neonates and infants: a retrospective evaluation.
    Asbury WH; Darsey EH; Rose WB; Murphy JE; Buffington DE; Capers CC
    Ann Pharmacother; 1993 Apr; 27(4):490-6. PubMed ID: 8477127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of Bayesian Area Under the Concentration-Time Curve-Based Pharmacokinetic Dosing Based on a One-Compartment Model and Trough-Only Monitoring for Vancomycin.
    Salehpour N; Riley LD; Gonzales MJ; Kobic E; Nix DE
    Antimicrob Agents Chemother; 2023 Jun; 67(6):e0017223. PubMed ID: 37133362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Towards precision dosing of vancomycin: a systematic evaluation of pharmacometric models for Bayesian forecasting.
    Broeker A; Nardecchia M; Klinker KP; Derendorf H; Day RO; Marriott DJ; Carland JE; Stocker SL; Wicha SG
    Clin Microbiol Infect; 2019 Oct; 25(10):1286.e1-1286.e7. PubMed ID: 30872102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non steady state and steady state PKS Bayesian forecasting and vancomycin pharmacokinetics in ICU adult patients.
    Polard E; Le Bouquin V; Le Corre P; Kérebel C; Trout H; Feuillu A; Le Verge R; Mallédant Y
    Ther Drug Monit; 1999 Aug; 21(4):395-403. PubMed ID: 10442692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accuracy of Bayesian, Sawchuk-Zaske, and nomogram dosing methods for vancomycin.
    Garrelts JC; Godley PJ; Horton MW; Karboski JA
    Clin Pharm; 1987 Oct; 6(10):795-9. PubMed ID: 3505841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vancomycin dosage requirements among pediatric intensive care unit patients with normal renal function.
    Glover ML; Cole E; Wolfsdorf J
    J Crit Care; 2000 Mar; 15(1):1-4. PubMed ID: 10757191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a pediatric continuous-infusion vancomycin therapy guideline.
    McKamy S; Chen T; Lee M; Ambrose PJ
    Am J Health Syst Pharm; 2012 Dec; 69(23):2066-71. PubMed ID: 23172265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accuracy of predicting the vancomycin concentration in Japanese cancer patients by the Sawchuk-Zaske method or Bayesian method.
    Nakashima T; Ohno T; Koido K; Hashimoto H; Terakado H
    J Oncol Pharm Pract; 2020 Apr; 26(3):543-548. PubMed ID: 31142231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a two-compartment Bayesian forecasting program for predicting vancomycin concentrations.
    Rodvold KA; Pryka RD; Garrison M; Rotschafer JC
    Ther Drug Monit; 1989; 11(3):269-75. PubMed ID: 2728085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vancomycin serum concentrations in pediatric oncologic/hematologic intensive care patients.
    Silva DC; Seixas GT; Araujo OR; Arduini RG; Carlesse FA; Petrilli AS
    Braz J Infect Dis; 2012; 16(4):361-5. PubMed ID: 22846125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vancomycin dosing in children and young adults: back to the drawing board.
    Camaione L; Elliott K; Mitchell-Van Steele A; Lomaestro B; Pai MP
    Pharmacotherapy; 2013 Dec; 33(12):1278-87. PubMed ID: 24019205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vancomycin monitoring: one or two serum levels?
    Andrés I; López R; Pou L; Piñol F; Pascual C
    Ther Drug Monit; 1997 Dec; 19(6):614-9. PubMed ID: 9421100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A population pharmacokinetic model for vancomycin in pediatric patients and its predictive value in a naive population.
    Lamarre P; Lebel D; Ducharme MP
    Antimicrob Agents Chemother; 2000 Feb; 44(2):278-82. PubMed ID: 10639350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of intravenous vancomycin in pediatric cardiopulmonary bypass surgery.
    Hatzopoulos FK; Stile-Calligaro IL; Rodvold KA; Sullivan-Bolyai J; Del Nido P; Levitsky S
    Pediatr Infect Dis J; 1993 Apr; 12(4):300-4. PubMed ID: 8483624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients.
    Eiland LS; English TM; Eiland EH
    Ann Pharmacother; 2011 May; 45(5):582-9. PubMed ID: 21521865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vancomycin in Pediatric Patients with Solid or Hematological Malignant Disease: Predictive Performance of a Population Pharmacokinetic Model and New Optimized Dosing Regimens.
    Marsot A; Gallais F; Galambrun C; Coze C; Blin O; Andre N; Guilhaumou R
    Paediatr Drugs; 2018 Aug; 20(4):375-381. PubMed ID: 29736878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.